Kitazawa Koji, Wakimasu Koichi, Kayukawa Kanae, Sugimoto Manabu, Nakai Junko, Weiss Jayne S, Ueno Morio, Sotozono Chie, Kinoshita Shigeru
Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Baptist Eye Institute, Kyoto, Japan.
Cornea. 2018 May;37(5):554-559. doi: 10.1097/ICO.0000000000001511.
To investigate the long-term surgical outcome after penetrating keratoplasty in 5 patients from 1 pedigree with Schnyder corneal dystrophy (SCD), resulting from the same UbiA prenyltransferase domain containing 1 (UBIAD1) mutation.
This retrospective study involved 6 eyes of 5 patients who underwent penetrating keratoplasty for treatment of SCD. Postoperative surgical outcome measures included the analysis of best-corrected visual acuity (BCVA), corneal endothelial cell density, and the rates of corneal graft rejection and disease recurrence. Genomic DNA was extracted from whole peripheral blood samples obtained from each patient at the time of surgery, and mutation analysis of the UBIAD1 gene was then performed.
All patients were found to have the same G177E mutation in the UBIAD1 gene. Mean patient age at the time of surgery was 61.5 ± 10.4 years (range, 49-72 yrs), and mean postoperative follow-up period was 8.8 ± 3.1 years (range, 3-11 yrs). Preoperatively, BCVA ranged from logarithm of the minimum angle of resolution (logMAR) 1.7 to logMAR 0.22; yet, it was found that BCVA had improved to logMAR 0.02 at 3 years postoperatively. Mean corneal endothelial cell density at 3, 5, and 8 years postoperatively was 2181, 1783, and 910 cells/mm, respectively. In all eyes, no disease recurrence or corneal graft rejection was observed during the follow-up period, and graft transparency was maintained.
Our findings show that the corneal grafts in the reported SCD pedigree remained clear with no rejection or disease recurrence over the long term.
研究来自同一个患有施奈德角膜营养不良(SCD)家系的5例患者行穿透性角膜移植术后的长期手术效果,这些患者均由相同的含1个泛醇化酶结构域蛋白1(UBIAD1)突变引起。
这项回顾性研究纳入了5例因SCD接受穿透性角膜移植术的患者的6只眼。术后手术效果评估指标包括最佳矫正视力(BCVA)分析、角膜内皮细胞密度以及角膜移植排斥反应和疾病复发率。从每位患者手术时采集的全外周血样本中提取基因组DNA,然后进行UBIAD1基因的突变分析。
所有患者均被发现UBIAD1基因存在相同的G177E突变。手术时患者的平均年龄为61.5±10.4岁(范围49 - 72岁),术后平均随访期为8.8±3.1年(范围3 - 11年)。术前,BCVA范围从最小分辨角对数(logMAR)1.7至logMAR 0.22;然而,发现术后3年BCVA改善至logMAR 0.02。术后3年、5年和8年的平均角膜内皮细胞密度分别为2181个、1783个和910个细胞/mm²。在所有眼中,随访期间均未观察到疾病复发或角膜移植排斥反应,且移植片保持透明。
我们的研究结果表明,在所报道的SCD家系中,角膜移植片长期保持清晰,无排斥反应或疾病复发。